Search research articles
Contact Us
Filters
Showing results (91-100 of 139) with videos related to
Page
of 14
Sort By:
Blood Advances
|
January 11, 2022
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
Ajlan Al Zaki, Lei Feng, Grace Watson, et al.
Haematologica
|
November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
Raphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
JAMA Oncology
|
July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial
Chelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Nature Communications
|
August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Paolo Strati, Lei Feng, Jason R Westin, et al.
American Journal of Cancer Research
|
October 13, 2022
Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up
Wanying Liu, Qingqing Cai, Tiantian Yu, et al.
Haematologica
|
August 1, 2020
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
Paolo Strati, Ankur Varma, Sherry Adkins, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
JAMA Network Open
|
September 29, 2020
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy
Chelsea C Pinnix, Jillian R Gunther, Penny Fang, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Blood Immunology & Cellular Therapy
|
July 8, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART
Kunhwa Kim, Zachary Hunzeker, Xiaowen Sun, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 139) with videos related to
Sort By:
Page
of 14
Blood Advances
|
January 11, 2022
Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy
Ajlan Al Zaki, Lei Feng, Grace Watson, et al.
Haematologica
|
November 11, 2021
Cardiovascular events in patients treated with chimeric antigen receptor T-cell therapy for aggressive B-cell lymphoma
Raphael E Steiner, Jose Banchs, Efstratios Koutroumpakis, et al.
JAMA Oncology
|
July 11, 2024
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial
Chelsea C Pinnix, Bouthaina S Dabaja, Jillian R Gunther, et al.
Nature Communications
|
August 7, 2025
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial
Paolo Strati, Lei Feng, Jason R Westin, et al.
American Journal of Cancer Research
|
October 13, 2022
Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up
Wanying Liu, Qingqing Cai, Tiantian Yu, et al.
Haematologica
|
August 1, 2020
Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
Paolo Strati, Ankur Varma, Sherry Adkins, et al.
American Journal of Hematology
|
January 12, 2017
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
Elias Jabbour, Paolo Strati, Monica Cabrero, et al.
JAMA Network Open
|
September 29, 2020
Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy
Chelsea C Pinnix, Jillian R Gunther, Penny Fang, et al.
Cancer
|
November 21, 2014
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
Elias J Jabbour, Guillermo Garcia-Manero, Paolo Strati, et al.
Blood Immunology & Cellular Therapy
|
July 8, 2026
Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART
Kunhwa Kim, Zachary Hunzeker, Xiaowen Sun, et al.
Page
of 14